Papaverine with radiation for advanced rectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests if adding papaverine (a drug) to radiation therapy can help people with locally advanced rectal cancer avoid surgery and keep their rectum. It is for patients who have already had chemotherapy and want a non-surgical approach.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of rectal cancer that has grown into nearby tissue or lymph nodes but hasn't spread to other organs.
- Your tumor is microsatellite stable (MSS), meaning it doesn't have certain genetic changes that make it more treatable with immunotherapy.
- You are willing to have imaging scans (fMRI), provide blood and stool samples, and donate some tumor and healthy tissue for research.
- You are in generally good health (ECOG score 0-2, meaning you are up and active) and have adequate blood counts, kidney, and liver function.
- You are at least 18 years old and, if you could become pregnant, agree to use birth control during and for 4 months after the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether adding epacadostat (a cancer drug) to standard pre-operative chemoradiation can improve outcomes for people with locally advanced rectal cancer. It’s designed to see if the added treatment is safe and potentially more effective before surgery.
This trial tests a combination of short-course radiation, chemotherapy (capecitabine), and two immunotherapy drugs (PD-1 and CTLA-4 inhibitors) for people with early-stage rectal cancer who want to avoid surgery and keep their anus. The goal is to see if this treatment can shrink the tumor enough to avoid major surgery.
This trial tests a combination of radiation, chemotherapy, and immunotherapy drugs before surgery for people with locally advanced rectal cancer. The goal is to shrink the tumor and improve outcomes for patients with higher-risk disease.
This trial combines a special type of radiation (MRI-guided adaptive radiotherapy) with an immunotherapy drug (PD-1 antibody) and chemotherapy (CAPOX) for locally advanced rectal cancer. The goal is to see if this combination can improve treatment outcomes.
This trial tests whether adding radiation therapy to a combination of chemotherapy (CAPOX) and an immunotherapy drug (PD-1 antibody) is more effective than the combination alone for people with locally advanced rectal cancer that is MSS (microsatellite stable) or pMMR. It aims to improve outcomes for patients with high-risk features.
This Phase 1 study tests a radiation treatment approach guided by MRI scans to help keep nearby organs functioning while treating rectal cancer. It is designed to find a safe, effective way to target the tumor and adjust treatment during the course of therapy.
Hear when a new Locally Advanced Rectal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.